Mouse Anti-CSNK2B Recombinant Antibody (CBFYC-2312) (V2LY-0125-LY55)

Wilke, M. V., Oliveira, B. M., Pereira, A., Doriqui, M. J. R., Kok, F., & Souza, C. F. (2022). Two different presentations of de novo variants of CSNK2B: two case reports. Journal of Medical Case Reports, 16(1), 1-6.

Selvam, P., Jain, A., Cheema, A., Atwal, H., Forghani, I., & Atwal, P. S. (2021). Poirier–Bienvenu neurodevelopmental syndrome: A report of a patient with a pathogenic variant in CSNK2B with abnormal linear growth. American Journal of Medical Genetics Part A, 185(2), 539-543.

Yu, S., Hu, Q., Fan, K., Yang, C., & Gao, Y. (2021). CSNK2B contributes to colorectal cancer cell proliferation by activating the mTOR signaling. Journal of Cell Communication and Signaling, 15(3), 383-392.

Yu, S., Li, L., Cai, H., He, B., Gao, Y., & Li, Y. (2021). Overexpression of NELFE contributes to gastric cancer progression via Wnt/β-catenin signaling-mediated activation of CSNK2B expression. Journal of Experimental & Clinical Cancer Research, 40(1), 1-16.

Yang, S., Wu, L., Liao, H., Lu, X., Zhang, X., Kuang, X., & Yang, L. (2021). Clinical and genetic analysis of six Chinese children with Poirier-Bienvenu neurodevelopmental syndrome caused by CSNK2B mutation. neurogenetics, 22(4), 323-332.

Li, J., Gao, K., Cai, S., Liu, Y., Wang, Y., Huang, S., ... & Jiang, Y. (2019). Germline de novo variants in CSNK2B in Chinese patients with epilepsy. Scientific reports, 9(1), 1-8.

Nakashima, M., Tohyama, J., Nakagawa, E., Watanabe, Y., Siew, C. N. G., Kwong, C. S., ... & Matsumoto, N. (2019). Identification of de novo CSNK2A1 and CSNK2B variants in cases of global developmental delay with seizures. Journal of human genetics, 64(4), 313-322.

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols